Supplemental Information Related to
Equity Compensation Expense:
Nine Months
Ended March 31,
2008 2007
1st Quarter Equity Compensation
Expense Prior to Acceleration
(includes mark-to-market adjustment
for stock appreciation rights
before and after acceleration) $0.7 $0.7
2nd & 3rd Quarter Equity
Compensation Expense $1.0 $1.7
Equity Compensation Related to
Acceleration of Stock Awards $3.0 -
Total Equity Compensation Expense $4.7 $2.4
Equity Compensation Expense Per
Share (net of tax) $0.25 $0.13
Biomaterials Update. Biomaterials sales for the third quarter and nine
months of fiscal 2008 increased to $12.6 and $34.2 million, respectively,
from $11.6 and $31.4 million, respectively, in the prior fiscal year
periods. Additional details are summarized below:
Three Months Year Nine Months Year
Ended over Ended over
March 31, Year % March 31, Year %
($ millions) 2008 2007 Change 2008 2007 Change
Orthopaedic Products $7.7 $7.1 8% $21.1 $15.8 33%
Cardiovascular Products $4.3 $4.0 9% $11.7 $14.4 (19%)
Other Products $0.6 $0.5 2% $1.5 $1.2 22%
Total Net Sales -
Biomaterials $12.6 $11.6 8% $34.2 $31.4 9%
"Our biomaterials sales of $12.6 million for the third quarter set a
record high with great contribution from our orthopaedic product sales
which have s
'/>"/>
| SOURCE Kensey Nash Corporation Copyright©2008 PR Newswire. All rights reserved |